Bank Julius Baer & Co. Ltd Zurich Has $4.93 Million Holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Bank Julius Baer & Co. Ltd Zurich reduced its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 4.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 54,176 shares of the company's stock after selling 2,504 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich's holdings in BioNTech were worth $4,933,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in BioNTech by 22.2% during the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after purchasing an additional 1,401,547 shares during the last quarter. Capital International Investors grew its position in shares of BioNTech by 38.6% during the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after buying an additional 394,434 shares during the period. Bank of New York Mellon Corp grew its position in shares of BioNTech by 18,892.9% during the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after buying an additional 694,691 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of BioNTech during the 4th quarter worth about $69,999,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after buying an additional 433,388 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

BNTX traded up $0.74 during trading hours on Friday, reaching $115.31. The company's stock had a trading volume of 392,122 shares, compared to its average volume of 579,799. BioNTech SE Sponsored ADR has a 52 week low of $76.53 and a 52 week high of $131.49. The company's 50-day moving average is $107.05 and its 200-day moving average is $106.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The firm has a market cap of $27.72 billion, a PE ratio of -33.91 and a beta of 1.29.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. The Goldman Sachs Group assumed coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective for the company. Morgan Stanley boosted their target price on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Finally, JPMorgan Chase & Co. cut their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $136.58.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.